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Summary 
 
The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia 
(CMML) are usually reported together with other categories of myelodysplastic syndrome. We 
analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years 
reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard 
(n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or 
unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, 
no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2–4 acute graft-
versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 
24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, 
resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. 
Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer 
relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only 
significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). 
Allo-SCT remains a curative treatment option for patients with CMML and should preferably be 
performed early after diagnosis or after establishing the best possible remission status. 
Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder sharing 
hybrid features of both a myelodysplastic syndrome (MDS) and a myeloproliferative neoplasm 
(MPN). The World Health Organization (WHO) 2000 classification characterized CMML as a 
hybrid MDS/MPN disorder, subdivided into two main sub-forms (Bennett, 2000). CMML patients 
  
are classified according to their baseline white blood cell (WBC) count, and those presenting with 
≤13 × 109/l WBC, not rapidly increasing, are classified as dysplastic CMML (CMML-D), whereas 
patients presenting with WBC > 13 × 10
9
/l, steadily increasing thereafter, are classified as 
proliferative CMML (CMML-P) (Bennett, 2000). CMML-D exhibits less prominent leucocytosis, a 
more stable clinical course and rather longer median survival. CMML-P is associated with more 
prominent leucocytosis, more rapid clinical course and shorter survival. The prognosis of this 
disease varies widely, with an overall survival (OS) ranging from a few months to many years. 
Nevertheless, it has been questioned whether an arbitrarily defined cut-off value of 13 × 10
9
/l WBC 
at baseline can distinguish clearly two disease subtypes. A retrospective analysis of 213 patients 
identified anaemia, circulating blast cells, absolute lymphocyte count >2·5 × 10
9
/l, and bone 
marrow (BM) blasts >10% as predictors of shorter OS (Onida et al, 2002). These four factors were 
used to create a prognostic score that could stratify disease risk (Onida et al, 2002). TheWHO 2008 
classification distinguishes CMML according to the percentage of BM blasts, as CMML-1 
(blasts < 10%) and CMML-2 (blasts ≥ 10%), and removed the dysplastic/proliferative 
characteristics from the subclassification (Vardiman et al, 2002). In recent years several prognostic 
scoring systems have been developed, most of which include cytogentic and molecular 
abnormalities (Itzykson et al, 2013; Patnaik et al, 2013; Such et al, 2013; Wassie et al, 2014). 
Standard treatment approaches include supportive transfusions, use of erythropoietin for the 
correction of anaemia and hydroxycarbamide or other single agents for controlling excess 
leucocytosis. More recently, the use of hypomethylating agents has been associated with a response 
rate of about 25%, less than what is usually observed in patients with classic MDS (Aribi et al, 
2007; Wijermans et al, 2008). Imatinib may induce temporary responses in rare cases associated 
with the t(5;12) translocation (Magnusson et al, 2002). Despite all these approaches, the median 
survival from diagnosis is 20–25 months (Onida et al, 2002; Beran et al, 2007). Allogeneic stem 
cell transplantation (allo-SCT) is the only curable treatment, but few studies have focused on the 
factors and conditions that would favour or discourage the application of allo-SCT in CMML. In 
most reports, results of allo-SCT in CMML were analysed together with the results of MDS or 
MPN and therefore were not particularly informative for CMML (Demuynck et al, 1996; Arnold 
et al, 1998; Deeg et al, 2000; Mittal et al, 2004; Warlick et al, 2009). In a previous report from the 
Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation 
(CLWP-EBMT) on 50 patients transplanted mainly from human leucocyte antigen (HLA)-matched 
related donors, the estimated 5-year OS was 21% and the disease-free survival (DFS), 18% (Kröger 
et al, 2002). Earlier transplantation, male donor, use of unmanipulated grafts and occurrence of 
acute graft-versus-host disease (GvHD), favoured better DFS (Kröger et al, 2002). Results from the 
Mayo Clinic implied the existence of a graft-versus-CMML effect, because the relapse of some 
patients was controlled with donor lymphocyte infusions (DLI) (Elliott et al, 2006). According to 
the Seattle experience, neither the MD Anderson prognostic score nor the WHO classification but 
only a higher comorbidity score adversely influenced the outcome (Depil et al, 2004; Kerbauy et al, 
2005). Nevertheless, the number of patients in these studies was small. The WHO classifications 
may have an impact on survival in general, but it is not known whether they also influence the 
outcome of patients undergoing allo-SCT. In addition, general prognostic factors, such as disease 
status at SCT, intensity of the conditioning regimen, stem cell source, T-cell depletion and GvHD 
may also affect transplantation outcome in this disease. 
The main objectives of this retrospective study were (i) to analyse non-relapse mortality (NRM), 
relapse incidence, relapse-free survival (RFS) and OS after allo-SCT in CMML cases registered in 
the EBMT database and (ii) to identify general prognostic factors. 
  
Patients and methods 
By the end of 2010, 513 patients with CMML were transplanted and registered in the EBMT 
database. Patients younger than 18 years at time of transplantation or patients diagnosed with 
juvenile myelomonocytic leukaemia (JMML) were excluded from this analysis. 
Statistics 
The following factors were investigated in univariate analysis: patient's age at transplantation, 
cytogenetics, WHO classification of CMML, interval from diagnosis to transplant, the inclusion of 
total body irradiation (TBI) in the conditioning, intensity of the conditioning, stem cell source, 
in vivo and/or ex vivo T-cell depletion of the graft, HLA-type of the donor (related or unrelated), 
year of transplantation, disease status at transplantation [complete remission (CR) versus no CR], 
donor-recipient gender match and the manifestation of acute or chronic GvHD. CR prior to 
transplantation was defined by a marrow blast count below 5% and a normalization of peripheral 
blood counts for at least 4 weeks. 
Statistical analysis was performed by using IBM spss Statistics for Windows, Version 20.0 
(Armonk, NY, USA) and R http://www.R-project.org) software. The time intervals for all outcomes 
(OS, RFS, relapse incidence and NRM) were measured from the day of allo-SCT onward. RFS 
indicates the probability of being alive and relapse-free. Differences between groups in OS and RFS 
were assessed by the log rank test. The impact of GvHD was investigated by means of Cox models, 
in which acute GvHD or chronic GvHD was entered as a time-dependent event. Relapse and NRM 
were considered as competing events and were analysed by means of cumulative incidence curves, 
comparing groups by a score test in a Cox model with a single factor (equivalent to the log rank test 
for OS and RFS). Cox proportional hazards regression models were fitted to examine the impact of 
risk factors on time to event outcomes. All significant variables identified by univariate analysis and 
clinical factors important for CMML were used to develop the multivariate model. Significant 
factors were identified by means of stepwise forward and backward selection. Confidence intervals 
were estimated at 95% level; all tests were two-sided, accepting P < 0·05 as indicative of a 
statistically significant difference. 
Results 
A total of 513 patients with CMML transplanted before 31 December 2009 and registered in the 
EBMT database were analysed in this study. The male to female ratio was 2·01, and the median age 
at transplantation was 53·1 years. Two hundred and fourteen (41·7%) were transplanted when aged 
≤50 years, whereas the remaining 299 patients (58·3%) were >50 years old at transplantation. Allo-
SCT was performed at a median of 9 months following initial diagnosis of CMML. The karyotype 
was available in 164 patients; 60 patients had various cytogenetic abnormalities. Due to the 
limitation of availability of detailed cytogenetic data we could classify the patients only according 
to normal and ‘abnormal’ cytogenetics. One hundred and twenty-eight patients (28%) had not 
received any disease modifying treatment before allo-SCT, whereas 338 patients (72%) had been 
treated with an interventional approach and of those, 43% had primary refractory or 
relapsed/progressive disease and 26% were in complete remission at time of transplantation. 
Demographic and cytogenetic data of the analysed patient population, as well as data concerning 
WHO 2000 and WHO 2008 classification, the intensity of the conditioning regimen, administration 
of TBI in the conditioning, donor/recipient relationship and matching, disease status at 
transplantation, stem-cell source, T-cell depletion of the graft and the period of transplantation are 
  
presented in Table 1. 
Table 1. Patient demographics, disease- and procedure-features 
 
CMML-D, chronic myelomonocytic leukaemia dysplastic type; CMML-P, chronic myelomonocytic 
leukaemia proliferative type; CMML-1, chronic myelomonocytic leukaemia type 1 (<10% BM 
blasts); CMML-2, chronic myelomonocytic leukaemia type 2 (≥10% BM blasts); SCT, stem cell 
transplantation; CR, complete response; BM, bone marrow; PB, peripheral blood. 
Engraftment and GvHD 
Engraftment was successful in 95% of the patients, 19 patients (3·9%) did not engraft and the graft 
was lost in the remaining 4 patients (0·8%). Acute GvHD of grade 0–1 occurred in 315 patients 
  
(67%), and grade 2–4 in 155 (33%). Maximum chronic GvHD was reported in 374 patients, it was 
absent in 106 (28%), limited in 58 (15%) and extensive in 65 patients (17%). 
Non-relapse mortality 
At the time of this analysis 277 patients have died (54%) of whom 103 (37%) died after relapse or 
disease progression. The cumulative incidence of NRM at one and at 4 years was 31% and 41%, 
respectively. One hundred and seventy-four patients died from NRM; causes of death were GvHD 
(23%), infectious complications (31%), toxicity and multi organ failure (19%) or other causes 
(27%). The NRM was significantly lower when the transplant was performed after 2002 (26% vs 
40%, P = 0·006) (Fig 1) and lower (borderline significant) if the transplant was performed in the 
first year after diagnosis (29% vs 34%, P = 0·07). The NRM at 1 year did not differ significantly 
between CMML-1 (27%), CMML-2 (34%) and secondary/transformed acute myeloid leukaemia 
(sAML) (25%, P = 0·91). 
 
Figure 1. Cumulative incidence of non-relapse mortality according to time of transplantation 
(before 2002 and after 2002). 
Relapse/relapse-free and OS 
The cumulative incidence of relapse at 4 years was 32%, resulting in an estimated 4-year RFS and 
OS of 27% and 33%, respectively (Table 2). 
 
Table 2. Results 
  
  
 
 
Impact of WHO 2000 and WHO 2008 classification 
 
Information regarding the WHO 2008 classification in CMML was available for 210 patients, 87 of 
whom were classified as CMML-1, 32 patients as CMML-2 and 95 patients as sAML evolving 
from previous CMML. There was no significant difference between CMML-1, CMML-2 and 
sAML regarding incidence of relapse at 4 years: 34% vs. 42% (P = 0·19), RFS at 4 years: 27% vs. 
21% vs. 20% (P = 0·39) and OS at 4 years: 30% vs. 26% vs. 33% (P = 0·54). Additionally, 
according to the WHO 2000 classification, 73 out of 183 patients were classified as CMML-D 
(39·9%) and 110 as CMML-P (60·1%). There was no significant impact of the WHO 2000 
classification on RFS, OS and any other transplantation outcomes. Similarly, the Kaplan–Meier (K-
M) estimates for RFS and for OS were not significantly different in patients with CMML-1, 
CMML-2, sAML and CMML of unspecified type (data not shown). 
 
Impact of disease status at transplantation 
 
Relapse incidence was not different between patients transplanted in CR and those who were not in 
CR at transplantation. However, K-M estimates of both RFS and OS were significantly longer for 
patients transplanted in CR {median 20·8 months [95% confidence interval (CI) 7·5–34·2] vs. 
7·6 months (95% CI 6·1–9·0), P = 0·001, and a median of 29·8 months (95% CI 4·0–55·6), vs. 
12·4 months (95% CI 10·0–14·8) P = 0·005, respectively}. K-M probabilities for RFS and OS at 
48 months were higher among patients transplanted in CR (36% vs. 24% and 42% vs. 30%, 
respectively) whereas the probability of non-relapse death at 1 year was lower (25% vs. 33%, 
P = 0·002). Thus, being in CR at transplantation, significantly affected outcome in allotransplanted 
patients with CMML in this analysis (Fig 2). 
 
 
 
 
 
 
 
 
Table 3. Factors affecting transplantation outcome in univariate analysis. P-values are 
derived from score-tests in univariate Cox models (equivalent to log-rank test) 
 
  
 
 
 
CR, complete remission; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; 
BM, bone marrow; PBSCT, peripheral blood stem cells; sAML, secondary acute myeloid 
leukaemia; NRM, non-relapse mortality; RFS, relapse-free survival; OS, overall survival. 
Significant and clinically relevant P-value are given in bold value. 
 
Multivariate analysis 
We performed a multivariate analysis to investigate the following factors, which might influence 
transplantation outcome including disease-related factors (WHO 2001 and WHO 2008 
classification, disease status at transplantation), patient-related factors (age at transplantation, time 
interval between diagnosis and transplantation) and procedure-related factors (chronological period 
of transplantation, standard versus reduced intensity conditioning (RIC), stem-cell source, donor 
type, T-cell depletion). The only factor with a clear impact on survival was disease status at 
transplantation, and patients transplanted not in CR had significantly decreased RFS and OS 
compared to those transplanted in CR [Hazard ratio (HR) for RFS = 1·65, P = 0·001; HR for 
OS = 1·55, P = 0·005]. 
Discussion 
Chronic myelomonocytic leukaemia (CMML) is difficult to treat and its course is rarely influenced 
by the available treatment approaches used in patients with MDS or MPN (Bacher et al, 2011). 
Therefore, allo-SCT appears a rational and attractive approach for patients with a suitable stem-cell 
donor. In a previous report from the CLWP-EBMT on 50 patients transplanted mainly from HLA-
matched-related donors, the estimated 5-year OS was 21% and DFS was 18% (Kröger et al, 2002). 
Earlier transplantation, male donor, use of unmanipulated grafts and occurrence of acute GvHD 
favoured better DFS. There was a trend for a lower probability of relapse in patients exhibiting 
grade II-IV acute GvHD, and for a higher relapse rate in patients with T cell-depleted grafts, 
suggesting a ‘graft-versus-CMML effect’ (Kröger et al, 2002). Such an effect was also 
demonstrated from the analysis of the Mayo Clinic, according to which two of the five patients who 
relapsed post-allo-SCT and received DLI achieved durable remissions for more than 15 months 
  
(Elliott et al, 2006). Some encouraging results have been obtained in Lille where DLI 
administration to 14 patients resulted in durable CR in 2 of them (Depil et al, 2004). Results from 
Seattle on 43 patients showed that 41% of them remained alive at 4 years post-transplant (Kerbauy 
et al, 2005). In this study neither the MD Anderson prognostic score nor the WHO classification 
had any influence on the outcome. The only factor that affected OS was a higher comorbidity score 
(Kerbauy et al, 2005). Similar results were obtained by other investigators analysing transplantation 
outcomes of patients with MDS and AML (Elliott et al, 2006; Boehm et al, 2008). The importance 
of early transplantation was also noted in an earlier study of 21 patients from Seattle (Zang et al, 
2000). Promising, although not mature, are the results of the analysis of 20 patients from MD 
Anderson of whom 8 had CMML (Mittal et al, 2004). After a median follow-up time of 
17·5 months, the actuarial OS at 2 years was 47%, and the DFS was 37% (Mittal et al, 2004). 
Nevertheless, in these retrospective studies the number of patients was usually small, some also 
included paediatric patients and in others results of CMML were not reported separately. Our study 
has analysed the largest cohort of transplanted adult patients with CMML ever published and has 
not included paediatric patients or patients with JMML. Our analysis has demonstrated that allo-
SCT may be a curative approach for more than one quarter of the patients, as 29% of them were 
long-term survivors beyond 60 months, and 26% were relapse-free with almost no additional events 
occurring after 36 months post-transplant. 
An interesting issue is the relevance of WHO classifications. Both systems have an impact on 
survival in non-transplanted patients, but it was not known whether they might influence 
transplantation outcome in patients undergoing allo-SCT. In our study there was a trend for 
improved RFS and OS for CMML-P vs. CMML-D as well as for CMML-1 vs. CMML-2 but, 
taking the relatively low number of patients with available data for WHO classification into 
account, we could not show that either WHO 2000 or WHO 2008 classification had any impact on 
the outcome, implying that the two classification systems do not describe different diseases but 
rather different phases of the same disease. Similar results were obtained from an analysis of 85 
patients transplanted in American centres (Eissa et al, 2011). In this study, age, comorbidity index, 
pre-transplant haematocrit and karyotype had a statistically significant impact on the outcome. 
However, the analysis also included paediatric patients who might have contributed to the better 
long-term outcome (Eissa et al, 2011). The significance of karyotype has also emerged from the 
analysis of the results from the King's College Hospital in London (Krishnamurthy et al, 2010), 
whereas in our analysis the karyotype did not influence NRM, RFS and OS but showed borderline 
significance (P = 0·07) for a higher risk of relapse for those patients with abnormal karyotype. 
However, due to the limitation of reported cytogenetic data in the registry it is very likely that more 
detailed information on cytogenetics, such as complex karyotype or monosomal karyotype, would 
show significant impact on outcome, as has been shown for MDS (Koenecke et al, 2015). 
We were unable to identify any procedure-related parameters, such as the intensity of the 
conditioning regimen, the stem-cell source, T-cell depletion of the graft, the type of donor etc., with 
an impact on the transplantation outcome. This has also been confirmed by other studies (Kerbauy 
et al, 2005) and is especially interesting, because it indicates that allo-SCT should be performed 
whenever a suitable donor is available and that ‘technical’ details do not influence the outcome. In 
this regard RIC regimens are not inferior to standard regimens and, in particular, can be applied to 
older and frailer patients. The efficacy of a RIC regimen has been demonstrated in a previous 
prospective trial of 37 patients with MDS/sAML, including three patients with CMML (Kröger 
  
et al, 2003) The use of RIC regimens may permit the application of allogeneic SCT in a broader 
patient population with acceptable toxicities (Laport et al, 2008). 
Our final analysis failed to demonstrate any significant impact of the presence and grading of acute 
and chronic GvHD. Acute GvHD, analysed as a time-dependent covariate, was not a significant 
factor for survival. The role of chronic GvHD might be similar to that in other diseases. However, 
given that the significance of this parameter has not been proven in the present analysis, the 
usefulness of administering post-transplant DLI to manage relapses remains at least controversial 
and certainly deserves to be studied in a prospective randomized trial. 
Thus, in our study, as also in others (Arnold et al, 1998; Laport et al, 2008; Warlick et al, 2009; 
Krishnamurthy et al, 2010) the most important parameter affecting transplantation outcome was 
disease status at the time of transplantation, and patients transplanted in CR clearly had a longer 
EFS and OS. Similar results have been obtained from retrospective analyses on patients with 
various other haematological dyscrasias, including MDS and AML. The clear message is that 
patients with CMML should be transplanted after achievement of the best possible remission status, 
either with combination chemotherapy or with epigenetic modifiers. In addition, early 
transplantation also appears to favourably influence the outcome of these patients. 
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